Neuronetics (STIM) Misses Q2 EPS by 6c ; Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. BROS
3. ARM
4. FIS
5. EXPE
6. QCOM
7. DDOG
8. PAYC
9. CHYM
10. CPAY

Go back to Neuronetics (STIM) Misses Q2 EPS by 6c ; Offers Guidance

Neuronetics (STIM) PT Lowered to $3 at Canaccord Genuity

August 13, 2024 6:23 AM EDT

Canaccord Genuity analyst William Plovanic lowered the price target on Neuronetics (NASDAQ: STIM) to $3.00 (from $6.00) while maintaining a Buy rating.

The analyst comments "Bottom line: STIMs Q2/24 missed estimates with $16.5M of revenue, driven by low treatment session revenue as customers delayed refilling inventory due to continued prior authorization and reimbursement headwinds from Change Healthcares cybersecurity breach impacting STIMs customer base. That said, STIM reiterated its FY24 revenue guidance of $78M-$80M, displaying confidence in the... More